WO2008098245A3 - Nmda receptor modulation and treatments for addictive behavior - Google Patents

Nmda receptor modulation and treatments for addictive behavior Download PDF

Info

Publication number
WO2008098245A3
WO2008098245A3 PCT/US2008/053584 US2008053584W WO2008098245A3 WO 2008098245 A3 WO2008098245 A3 WO 2008098245A3 US 2008053584 W US2008053584 W US 2008053584W WO 2008098245 A3 WO2008098245 A3 WO 2008098245A3
Authority
WO
WIPO (PCT)
Prior art keywords
nmda receptor
treatments
receptor modulation
addictive behavior
treating
Prior art date
Application number
PCT/US2008/053584
Other languages
French (fr)
Other versions
WO2008098245A2 (en
Inventor
John J Wagner
Original Assignee
Univ Georgia Reseach Foundatio
John J Wagner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia Reseach Foundatio, John J Wagner filed Critical Univ Georgia Reseach Foundatio
Publication of WO2008098245A2 publication Critical patent/WO2008098245A2/en
Publication of WO2008098245A3 publication Critical patent/WO2008098245A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The instant disclosure relates generally to methods for treating an individual with a psychiatric disorder with a pharmacologic agent that enhances learning or conditioning in combination with psychotherapy. In one aspect, the disclosure provides a method of treating addictive disorder comprising administering to a subject in need thereof a pharmaceutically effective amount of a NMDA receptor modulatory agent prior to, concurrent with, or following extinction training whereby the reinstatement of drug seeking behavior is reduced.
PCT/US2008/053584 2007-02-09 2008-02-11 Nmda receptor modulation and treatments for addictive behavior WO2008098245A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88895907P 2007-02-09 2007-02-09
US60/888,959 2007-02-09

Publications (2)

Publication Number Publication Date
WO2008098245A2 WO2008098245A2 (en) 2008-08-14
WO2008098245A3 true WO2008098245A3 (en) 2008-10-16

Family

ID=39682463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/053584 WO2008098245A2 (en) 2007-02-09 2008-02-11 Nmda receptor modulation and treatments for addictive behavior

Country Status (1)

Country Link
WO (1) WO2008098245A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076249A1 (en) * 2008-04-24 2010-03-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
KR20120113259A (en) * 2010-01-08 2012-10-12 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 D-amino acids for use in treating biofilms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137767A1 (en) * 1999-07-09 2002-09-26 Heal David John Methods for treating addictive disorders
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
US20040208923A1 (en) * 2001-03-29 2004-10-21 Michael Davis Acute pharmacologic augmentation of psyschotherapy with enhancers of learning or conditioning
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137767A1 (en) * 1999-07-09 2002-09-26 Heal David John Methods for treating addictive disorders
US20040208923A1 (en) * 2001-03-29 2004-10-21 Michael Davis Acute pharmacologic augmentation of psyschotherapy with enhancers of learning or conditioning
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors

Also Published As

Publication number Publication date
WO2008098245A2 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
WO2008036846A3 (en) Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
WO2008021389A3 (en) Using pi3k and mek modulators in treatments of cancer
WO2007109237A3 (en) Controlling an interactive story through manipulation of simulated character mental state
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2010011466A3 (en) Controlled-release cns modulating compositions and methods for the treatment of otic disorders
WO2006137106A3 (en) Method for the potentiation of opioid analgesics effects on pain
WO2007146411A3 (en) Nanoshell therapy
WO2010008995A3 (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
WO2008124681A3 (en) Methods and systems for treating cell proliferation disorders
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2009117710A3 (en) Methods of treating inflammation
HK1135269A1 (en) Apparatuses and methods for use in creating an audio scene
WO2008147622A3 (en) Customizing haptic effects on an end user device
MX2010004502A (en) Methods of treating urogenital-neurological disorders using modified clostridial toxins.
WO2006073872A3 (en) Retrograde perfusion of tumor sites
WO2007089715A3 (en) Method for treatment of neuropathic pain
WO2008150530A3 (en) Cripto binding molecules
WO2007130663A3 (en) Method, device, and system for delivery of therapeutic agents to the eye
WO2007087154A3 (en) Methods for enhancing therapeutic effects of a neurotoxin
WO2007105203A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2009002830A3 (en) Controlling access to multiple pieces of content of a presentation
WO2010059561A3 (en) Systems and methods for treatment of aneurysms using zinc chelator(s)
DK2051710T3 (en) Compositions and Methods for the Treatment, Reduction, Improvement or Relief of Disorders of the Rear Ocular Segment
WO2008118785A3 (en) Methods for treating depression using immediate-impact treatments and d-cycloserine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08729531

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08729531

Country of ref document: EP

Kind code of ref document: A2